Ignite Creation Date:
2025-12-24 @ 9:58 PM
Ignite Modification Date:
2025-12-25 @ 7:36 PM
Study NCT ID:
NCT00221832
Status:
UNKNOWN
Last Update Posted:
2010-01-13
First Post:
2005-09-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
Sponsor:
Heidelberg University
Organization:
Study Overview
Official Title:
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
Status:
UNKNOWN
Status Verified Date:
2003-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is the identification of familial congenital arrhythmogenic disorders and their clinical follow-up.
Detailed Description:
Molecular genetic screening in patients with:
* supraventricular
* ventricular arrhythmia
* syncopes of unknown origin and/or suspicion of an arrhythmogenic origin
* family members of patients with sudden cardiac death and aborted sudden cardiac death
Examination of patients includes routine testing like electrocardiogram (ECG), sequential ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome. Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular genetic screening.
* supraventricular
* ventricular arrhythmia
* syncopes of unknown origin and/or suspicion of an arrhythmogenic origin
* family members of patients with sudden cardiac death and aborted sudden cardiac death
Examination of patients includes routine testing like electrocardiogram (ECG), sequential ECGs, exercise testing, invasive electrophysiological stimulation, cardiac magnetic resonance imaging, intravenous drug challenge for identification/exclusion of eg Brugada syndrome. Examples are patients with Long QT Syndrome, Short QT Syndrome, Brugada Syndrome, familial atrial fibrillation, WPW-syndrome, arrhythmias due to familial hypertrophic cardiomyopathy or arrhythmogenic right ventricular dysplasia. Blood samples are taken for further molecular genetic screening.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: